for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca sells right to heart failure, blood pressure medicines for $400 mln

Oct 30 (Reuters) - AstraZeneca Plc said on Friday it had agreed to sell commercial rights for two of its heart failure and blood pressure medicines to German pharmaceutical company Cheplapharm Arzneimittel GmbH for $400 million.

Under the deal, Cheplapharm will get commercial rights for Atacand and Atacand Plus in around 70 countries globally, AstraZeneca said.

Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Sriraj Kalluvila

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up